Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Glimepiride in T2DM Patients on Insulin and Metformin
NCT01341717Phase 4Completed
- Sponsor
- Jothydev's Diabetes and Research Centre
- Start
- Feb 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Jothydev's Diabetes and Research Centre. Primary endpoint: Reduction in HbA1c from baseline at 6 months. Started Feb 2012; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01341717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01341717.